STOCKS TELEGRAPH

Tag: NASDAQ: ACB

  • 3 Stocks That Could Surprise You: Organigram Global (OGI), Aurora Cannabis (ACB), Cardiol Therapeutics (CRDL)

    3 Stocks That Could Surprise You: Organigram Global (OGI), Aurora Cannabis (ACB), Cardiol Therapeutics (CRDL)

    Healthcare and biotech micro-cap stocks are known for their volatility, with share prices often moving dramatically in response to clinical or corporate milestones. For investors, this presents both potential opportunities and risks, requiring close monitoring of pipeline updates and market sentiment.

    Organigram Global Inc (OGI)

    Organigram Global Inc (NASDAQ: OGI) open the trading on April 08, 2026, with great promise as it jumped 1.46% to $1.39. During the day, the stock rose to $1.44 and sunk to $1.38 before settling in for the price of $1.37 at the close. Taking a more long-term approach, OGI posted a 52-week range of $0.85-$2.24.

    The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 43.19%. Meanwhile, its Annual Earning per share during the time was 43.19%.  Nevertheless, stock’s Earnings Per Share (EPS) this year is 178.42%. This publicly-traded company’s shares outstanding now amounts to $135.13 million, simultaneously with a float of $92.19 million. The organization now has a market capitalization sitting at $189.51 million.

    Aurora Cannabis Inc (ACB)

    Aurora Cannabis Inc (NASDAQ: ACB) started the day on April 08, 2026, with a price increase of 1.78% at $3.43. During the day, the stock rose to $3.58 and sunk to $3.40 before settling in for the price of $3.37 at the close. Taking a more long-term approach, ACB posted a 52-week range of $3.07-$6.66.

    Nevertheless, stock’s Earnings Per Share (EPS) this year is -894.94%. This publicly-traded company’s shares outstanding now amounts to $56.71 million, simultaneously with a float of $56.41 million. The organization now has a market capitalization sitting at $194.52 million.

    Cardiol Therapeutics Inc (CRDL) — Micro-Cap with Multi-Program Potential

    Cardiol Therapeutics Inc (CRDL) remains a micro-cap biotech with multiple clinical programs, offering diversified upside despite recent market volatility. The company continues to build a foundation across several cardiovascular indications.

    Market Position

    Cardiol Therapeutics Inc (CRDL) closed at $1.29 after a -7.86% decline, reflecting short-term pressure. The stock trades within a 52-week range of $0.80 to $1.59, with approximately 111.68 million shares outstanding and a float of 107.08 million.

    Clinical Progress

    Cardiol Therapeutics is advancing CardiolRx™ across both pericarditis and myocarditis. The MAVERIC Phase III trial remains the primary catalyst, while ARCHER data provides cross-validation of the drug’s anti-inflammatory effects.

    Pipeline and Strategy

    CRDL’s pipeline includes both late-stage and early-stage assets, with CRD-38 targeting heart failure through anti-inflammatory mechanisms. Preclinical data supports its role in reducing fibrosis and preserving cardiac function.

    Industry Position

    Cardiol Therapeutics is positioned within a developing segment focused on inflammation in heart disease. As clinical validation increases, this niche may attract broader attention within the cardiovascular space.

  • Aurora Cannabis Inc. (ACB) Rockets Up in Cannabis Stock Surge During After-Hours

    Aurora Cannabis Inc. (NASDAQ: ACB) had a standout day on Friday, marking an impressive 10% surge in its stock price. However, the excitement didn’t stop there. As the market closed its doors for the day, Aurora experienced an astounding 17% boost in after-hours trading, catching the attention of investors and analysts alike.

    Industry Speculation and Market Trends

    The surge in Aurora’s stock price isn’t happening in isolation; it’s part of a broader trend within the cannabis industry. Insights from top analyst Doug Kass hint at significant developments on the horizon.

    Speculation suggests that the US Drug Enforcement Administration could soon approve a rescheduling of cannabis to Schedule III, alongside positive resolutions regarding international treaties. This speculation has ignited a wave of optimism among investors, positioning cannabis stocks for potential growth.

    The anticipation of regulatory shifts has led to a shift in investor sentiment, with many redirecting their focus from other sectors, such as AI, toward cannabis stocks in pursuit of short-term gains.

    Product Innovation and Market Expansion

    Beyond market speculation, Aurora Cannabis Inc. made headlines recently with its announcement of medical cannabis pastilles becoming available in Australia. These pastilles, developed by Aurora and distributed by MedReleaf Australia, provide physicians with a new avenue for prescribing medical cannabis to patients.

    With three variants available, including THC, CBD, and balanced options, Aurora aims to enhance access to premium medical cannabis products for Australian patients.

    Andre Jerome, Aurora’s Executive Vice President of Global Business Development, underscored the company’s dedication to supporting the growth of the Australian medical cannabis market. Kristin Viccars, Managing Director at MedReleaf Australia, emphasized the significance of innovation in broadening patient access to medical cannabis.

    Conclusion

    As Aurora Cannabis Inc. continues to innovate and expand its market reach, investors are closely monitoring industry developments. The surge in after-hours trading reflects growing optimism surrounding potential regulatory changes and Aurora’s commitment to product innovation.

    With all eyes on Aurora, the company stands poised to navigate the dynamic landscape of the cannabis market, capturing opportunities for growth and expansion.